OVID News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OV

Mkt Cap

$422.4M

Volume

1.05M

Next Earnings

November 11th

Loading chart

OV

OVIDOvid Therapeutics Inc. Common Stock

OVID

Pay with—

Available Balance0.00

OV

Mkt Cap

$441.4M

Volume

1.05M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in CologneBIO-Europe 2026 will host over 6,000 senior leaders from the global biopharma industry in Cologne, Germany, from November 9-11, 2026. The 32nd annual edition expands beyond partnering to become Europe's largest biopharma strategy forum, featuring seven integrated tracks covering regulatory, clinical, and manufacturing strategy, with focus on partnerships, innovation, and addressing industry challenges.GlobeNewswire Inc. · Sep 29, 2026

Here's Why Ovid Therapeutics Stock Popped Higher TodayOvid Therapeutics stock surged 18% following positive Phase 1 data for OV329, a next-generation GABA-AT inhibitor for epilepsy. The drug showed no treatment-related adverse events at 7mg dose and no ophthalmic changes, addressing safety concerns with existing treatments. The company announced a $60M private placement to fund Phase 2 trials and expansion into other indications.The Motley Fool · Mar 18, 2026

Ovid Therapeutics Announces Pricing of $60 Million Private PlacementOvid Therapeutics secured $60 million in private investment in public equity (PIPE) financing led by Point72, with participation from multiple hedge funds and asset managers. The company plans to use proceeds to expand development of OV329, a GABA-aminotransferase inhibitor, into tuberous sclerosis complex and infantile spasms indications, along with general R&D expenses.GlobeNewswire Inc. · Mar 18, 2026

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial ResultsOvid Therapeutics announced a CEO succession plan with Meg Alexander becoming CEO on January 1, 2026, and Dr. Jeremy M. Levin transitioning to Executive Chair. The company reported positive Phase 1 results for OV329, a next-generation GABA-AT inhibitor, and continues advancing its KCC2 direct activator portfolio.GlobeNewswire Inc. · Nov 12, 2025

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceOvid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that its President and COO will present at the upcoming TD Cowen conference. The company is advancing a pipeline of novel small molecule candidates for neurological and neuropsychiatric disorders.GlobeNewswire Inc. · Feb 27, 2025

Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsightThe epilepsy market is expected to grow due to an increase in disease prevalence and the launch of emerging therapies. The market is segmented into partial epilepsy, chronic focal epilepsy, and drug-resistant epilepsy, with various treatment options and pipeline drugs.GlobeNewswire Inc. · Feb 20, 2025

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceOvid Therapeutics, a biopharmaceutical company focused on brain conditions, announced that it will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025.GlobeNewswire Inc. · Feb 5, 2025

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous MalformationsNEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, and Graviton Bioscience Corporation, a privately held clinical-stage biotechnology company focused on developing Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitors and other innovative therapeutic compounds, today announced the results from their Phase 1 healthy volunteer study evaluating the safety, tolerability, and pharmacokinetic (PK) profile of multiple ascending doses of OV888/GV101 capsule. Ovid and Graviton plan to progress to a Phase 2 clinical study in cerebral cavernous malformations (CCM) later this year.GlobeNewswire Inc. · Jul 1, 2024

Wall Street Breakfast: The Week AheadStay up to date on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.Seeking Alpha · Jun 30, 2024

Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More NewsIntra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.Zacks Investment Research · Jun 20, 2024

to start trading

OV

OVIDOvid Therapeutics Inc. Common Stock

OVID

Pay with—

Available Balance0.00

Your PositionYou don't own any OVID yet.

Related Tickers

Earnings